Analysis of sGC subunits in SCLC biopsies or in readily accessed CTCs could provide a predictive biomarker of response to sGC pathway inhibition in a disease for which novel treatment strategies are urgently needed. This evidence concerns the gene SGCB and small cell lung carcinoma.